Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy

Muscle and Nerve

Volumn 44, Issue 2, 2011, Pages 170-173

  Zimmerman, Angela ^a   Clemens, Paula R ^b,c   Tesi Rocha, Carolina ^a   Connolly, Anne ^d   Iannaccone, Susan T ^e   Kuntz, Nancy ^f   Arrieta, Adrienne ^a   Hache, Lauren ^b   Henricson, Erik ^g   Hu, Fengming ^a   Mayhew, Jill ^h   Escolar, Diana M ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Children's Hospital of Virginia   (United States)

Author keywords

Clinical trial; Duchenne; Leukopenia; Muscular dystrophy; Pentoxifylline

Indexed keywords

PENTOXIFYLLINE;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MALE; MUSCLE FUNCTION; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CHILD; CHILD, PRESCHOOL; GASTROINTESTINAL DISEASES; HUMANS; LEUKOPENIA; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; PENTOXIFYLLINE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 79960518961     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22127     Document Type: Article

References (11)

1. Engel AG, Yamamoto M, Fischbeck KH. Dystrophinopathies. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 1994. p 1133-1187.
2. Coimbra R, Melbostad H, Hoyt DB. Effects of phosphodiesterase inhibition on the inflammatory response after shock: role of pentoxifylline. J Trauma 2004;56:442-449.
3. Shaw SM, Shah MKH, Williams SG, Fildes JE. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Failure 2009;11:113-118.
4. Sanofi-Aventis U.S. LLC. TRENTAL-pentoxifylline package insert; 2006.
5. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000;10:235-239.
6. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003 (http://ctep.cancer.gov); August 9, 2006
7. Hatcher RA. The mechanism of vomiting. Physiol Rev 1924;4:479-504.
8. Borrelli O, Salvia G, Mancini V, Santoro L, Tagliente F, Romeo EF, et al. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Am J Gastroenterol 2005;100:695-702.
9. Mule F, Amato A, Vannucchi MG, Gaussone-Pellegrini MS, Serio R. Altered tachykinergic influence on gastric mechanical activity in mdx mice. Neurogastroenterol Motil 2006;18:844-852.
10. Baccari MC, Nistri S, Vannucchi MG, Calamai F, Bani D. Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-medicated mechanism. Am J Physiol Regul Integr Comp Physiol 2007;293:R662-R668.
11. Baccari MC, Calamai F, Chiappini L, Vannucchi MG, Bani D. Relaxin restores altered ileal spontaneous contractions in dystrophic (mdx) mice. Ann NY Acad Sci 2005;1041:308-310.